Healthcare

PE HUB Healthcare Wire, 4.11.19

Trending this week: healthcare payer services

PE-backed StageBio and Tox Path Specialists merge

StageBio, which is backed by Ampersand Capital Partners, has merged with Tox Path Specialists. No financial terms were disclosed. Based in Mount Jackson, Virginia, StageBio is a provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. And, Frederick, Maryland-based Tox Path is a neuropathology lab

BioTek Instruments could sell for $1 bln: Bloomberg

BioTek Instruments Inc is exploring options including a sale, Bloomberg is reporting. Healthcare companies and investment funds have expressed a preliminary interest in BioTek, a U.S. medical device maker, the story said. BioTek could be valued at $1 billion, Bloomberg said.

Horizon Capital invests in Dobrobut

Horizon Capital said April 10 that it acquired a minority stake in Dobrobut. Financial terms weren’t announced. Dobrobut is a private healthcare services provider in Ukraine.

New Mountain's Convey Health seeks buyer

G Square Healthcare buys majority of Dental Care Group

G Square Healthcare Private Equity LLP said April 8 that acquired a majority of Dental Care Group. Financial terms weren’t announced. Dental Care is comprised of 21 dental practices in East and South East of England.

WCAS recruits Mendelson as operating partner for healthcare team

Welsh, Carson, Anderson & Stowe has named Dan Mendelson as an operating partner for the firm's healthcare team. Mendelson is the founder and former CEO of Avalere Health LLC.

Twin Brook appoints Wentink as MD for healthcare lending business

Twin Brook, Angelo Gordon‘s middle-market direct lending arm, has named Timothy Wentink as a managing director focused on its healthcare lending business. Previously, he worked at Madison Capital where he was a managing director on the healthcare leveraged finance team.

Apposite Capital invests in Mirada Medical

Apposite Capital said April 8 that it invested 6 million pounds ($7.8 million) of preferred equity in Mirada Medical, a medical imaging software company.

Intermediate Capital buys Doc Generici

Intermediate Capital Group said April 8 that it invested in Doc Generici. Mérieux Equity Partners invested in the deal. CVC is the seller. Financial terms weren’t announced. Doc Generici is a generic pharmaceutical company in Italy. Gattai, Minoli, Agostinelli & Partners advised Intermediate Capital.